Green light from the European Drug Agency Ema to the monoclonal antibody tocilizumab in seriously ill patients of Covid-19. The EU regulatory body’s CHMP Committee for Medicinal Products for Human Use recommended extending the indication of the drug (RoActemra *, Roche) to include treatment of Sars-CoV-2 infected adults who are receiving corticosteroid treatment systemically and requiring supplemental oxygen or mechanical ventilation.
The drug is already approved in the European Union for the treatment of inflammatory diseases such as rheumatoid arthritis, systemic juvenile idiopathic arthritis, juvenile idiopathic polyarthritis, giant cell arthritis and cytokine release syndrome (Crs).
#Covid #Ema #monoclonal #tocilizumab #ill #patients